SCHEMBL1490836

SCHEMBL1490836

CC(C)(C)OC(=O)NCCCn1c(CON2C(=O)c3ccccc3C2=O)nc2cnc3cccnc3c21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.40
CCNB2 O95067 1/20 0.40
PRKCB P05771 1/20 0.40
CDK1 P06493 1/20 0.40
LYN P07948 1/20 0.40
CCNB1 P14635 1/20 0.40
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
GSK3B P49841 1/20 0.40
RPS6KA3 P51812 1/20 0.40
CCNA1 P78396 1/20 0.40
CCNB3 Q8WWL7 1/20 0.40
KDM4E B2RXH2 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
STING1 Q86WV6 3/20 0.39
TLR8 Q9NR97 1/20 0.38
TLR7 Q9NYK1 1/20 0.38
DYRK1A Q13627 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5115537 0.86 STING1 (0.42) PDPK1CCNB2PRKCBCDK1LYN
SCHEMBL1231989 0.85 KDM4E (0.45) PDPK1CCNB2PRKCBCDK1LYN
SCHEMBL4638266 0.82 TDP1 (0.33) TDP1MEN1KMT2A
SCHEMBL4156877 0.82 KDM4E (0.44) KDM4ETDP1L3MBTL1STING1TLR8
SCHEMBL5124567 0.82 STING1 (0.46) KDM4ETDP1L3MBTL1STING1TLR7
SCHEMBL5129239 0.81 STING1 (0.46) KDM4ETDP1L3MBTL1STING1TLR8
SCHEMBL3355952 0.80 TLR7 (0.48) KDM4ETDP1L3MBTL1STING1TLR7
SCHEMBL4309229 0.79 STING1 (0.46) PDPK1CCNB2PRKCBCDK1LYN
SCHEMBL3353897 0.79 TLR7 (0.47) KDM4ETDP1L3MBTL1STING1TLR7
SCHEMBL12888449 0.79 KDM4E (0.44) KDM4ETDP1L3MBTL1STING1TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897767-B2 Oxime substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-03-01 US disclosed
US-20090042925-A1 OXIME SUBSTITUTED IMIDAZOQUINOLINES COLEY PHARMACEUTICAL GROUP, INC. 2009-02-12 US disclosed
EP-1685129-A4 OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS 3M INNOVATIVE PROPERTIES CO (US) 2008-10-22 EP disclosed
EP-1685129-A2 OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS 3M Innovative Properties Company (US) 2006-08-02 EP disclosed
WO-2005048933-A2 OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042925-A1 OXIME SUBSTITUTED IMIDAZOQUINOLINES IFNG, IL2, IRF3 PDPK1 3124/4885CCNB2 1154/4885PRKCB 3021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.